Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;15(11):2263-2278.
doi: 10.1007/s13300-024-01654-y. Epub 2024 Sep 30.

Criteria for Personalised Choice of a Continuous Glucose Monitoring System: An Expert Opinion

Sergio Di Molfetta #  1 , Antonio Rossi #  2 , Federico Boscari  3 , Concetta Irace  4 , Luigi Laviola  1 , Daniela Bruttomesso  3
Affiliations

Criteria for Personalised Choice of a Continuous Glucose Monitoring System: An Expert Opinion

Sergio Di Molfetta et al. Diabetes Ther. 2024 Nov.

Erratum in

Abstract

Despite the growing evidence supporting the outpatient use of continuous glucose monitoring (CGM) for improving glycaemic control and reducing hypoglycaemia, there is a need for a detailed understanding of the specific features of CGM devices that best meet individual patient needs. This expert opinion, based on a comprehensive literature review and the personal perspectives of clinicians, aims to provide the healthcare professionals (HCPs) with a comprehensive framework for selecting CGM devices. It evaluates the current state of CGM technology, categorizing features into essential features, major drivers of choice, and additional/useful features. Moreover, the practical model presented outlines a patient's journey with CGM, emphasising the importance of aligning device features with patient needs. This includes understanding the patient's lifestyle, clinical conditions, and personal preferences to optimize CGM use and improve diabetes management outcomes.

Keywords: Choice-driving factors; Continuous glucose monitoring; Diabetes technology; Sensor features.

PubMed Disclaimer

Conflict of interest statement

Sergio di Molfetta has received consulting fees from Roche Diabetes Care, Ascensia Diabetes Care, and Eli Lilly and received payment or honoraria for lectures, presentations, spekers bureaus, manuscript writing or education events from Movi S.p.A and Ascensia Diabetes Care. Antonio Rossi, in the last two years, has received speaking and/or consulting fees from AstraZeneza, Roche Diabetes Care, Menarini Diagnostics, Alpha Pharma, Abbott, Sanofi, and Theras. Federico Boscari has received consulting fees from Roche, and Glooko and received honoraria for lectures and presentations from Roche, Novo Nordisk, Sanofi Aventis, and Movi. Concetta Irace has provided advisory board services for Novo Nordisk, Lilly, Roche Diabetes Care Italy, Abbott, Menarini, Ascensia, and Senseonics and has received speaker fees from Novo Nordisk, Roche Diabetes Care Italy, Abbott, Ascensia, Lilly, and Boehringer Ingelheim Pharmaceuticals. Luigi Laviola has received consulting fees from Abbott, Boehringer Ingelheim, AstraZeneca, Eli Lilly Italia, GSK, Medtronic, Menarini, MOVI, Novo Nordisk, Roche Diabetes Care, Sanofi and honoraria for lectures and presentations from Abbott, Boehringer Ingelheim, AstraZeneca, Eli Lilly Italia, Medtronic, Menarini, MOVI, Mundipharma, Novo Nordisk, Roche Diabetes Care, Sanofi. Daniela Bruttomesso has received consulting fees from Menarini, Novo Nordisk, Roche, and Terumo and received honoraria for lectures and presentations from Abbott, Eli Lilly, Novo Nordisk, Roche, Sanofi Aventis, and Theras.

Figures

Fig. 1
Fig. 1
Classification of CGM features
Fig. 2
Fig. 2
Practical examples of matching device features with patient needs across various clinical scenarios
See this image and copyright information in PMC

References

    1. Internal Diabetes Federation, IDF diabetes atlas, 10th edition. Brussels, Belgium: 2021 IDF Diabetes Atlas.
    1. Lee I, Probst D, Klonoff D, Sode K. Continuous glucose monitoring systems—current status and future perspectives of the flagship technologies in biosensor research. Biosens Bioelectron. 2021;181:113054. - PubMed
    1. Mihai D, Stefan D, Stegaru D, et al. Continuous glucose monitoring devices: a brief presentation (review). Exp Ther Med. 2021;23:174. - PMC - PubMed
    1. Talbo MK, Katz A, Hill L, Peters TM, Yale J-F, Brazeau A-S. Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: a systematic review and meta-analysis. eClinicalMedicine. 2023. 10.1016/j.eclinm.2023.102119. - PMC - PubMed
    1. Dicembrini I, Cosentino C, Monami M, Mannucci E, Pala L. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58:401–10. - PubMed